Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

The Pharmalot View

By Ed Silverman

The Pharmalot View

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

By Ed Silverman

The Pharmalot View

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

By Ed Silverman

advertisement

The Pharmalot View

Drug makers deserve to be publicly shamed for thwarting competition from generics

By Ed Silverman

advertisement

The Pharmalot View

The art of the deal? Why a money-back guarantee for drugs is a bad idea

By Ed Silverman

The Pharmalot View

If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

By Ed Silverman

The Pharmalot View

It’s time to make it legal for Americans to order prescription drugs from abroad

By Ed Silverman

The Pharmalot View

US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

By Ed Silverman

advertisement

The Pharmalot View

The Trump administration could bring down drug prices. But it would take guts

By Ed Silverman

advertisement

The Pharmalot View

Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

By Ed Silverman

The Pharmalot View

How a $37,000-a-year medicine sets a good model for drug pricing

By Ed Silverman

The Pharmalot View

Here’s one drug safety rule the FDA should enact — quickly

By Ed Silverman

The Pharmalot View

Dear Mr. President: Your view of the FDA is misguided. Here’s why

By Ed Silverman

The Pharmalot View

Dear Vice President Pence: Stop peddling false hopes to dying patients

By Ed Silverman

The Pharmalot View

Pharma trade group vows to review membership criteria, but is this an empty promise?

By Ed Silverman

The Pharmalot View

Dear President Trump: Your big idea on drug pricing is half-baked

By Ed Silverman

The Pharmalot View

Drug industry ad campaign may be too late to save its reputation

By Ed Silverman

The Pharmalot View

Trump is considering a radical to lead FDA. That’s dangerous for public health

By Ed Silverman

The Pharmalot View

Trump should be good medicine for the pharmaceutical industry. Here’s why

By Ed Silverman

The Pharmalot View

Pharma may have defeated Prop 61, but state battles over pricing will continue

By Ed Silverman

The Pharmalot View

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

By Ed Silverman

The Pharmalot View

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

By Ed Silverman

The Pharmalot View

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

By Ed Silverman

The Pharmalot View

Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?

By Ed Silverman

The Pharmalot View

The secretive system for vetting cancer drug use needs an urgent overhaul

By Ed Silverman

The Pharmalot View

An open letter to Mylan CEO Heather Bresch about EpiPen pricing

By Ed Silverman

The Pharmalot View

Laws to shed light on drug pricing strategies probably won’t work

By Ed Silverman

The Pharmalot View

Pharma should not be allowed a loophole for reporting financial ties to docs

By Ed Silverman

The Pharmalot View

The ‘gouge factor’: Big companies want transparency in drug price negotiations

By Ed Silverman

The Pharmalot View

Pharma trade group says price gougers are outliers, but then accepts two more

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X